GRHL2 and neoplasm: Next, we compared accessibilities in subsamples with different tumor fractions for TFs selected based on our previous ATAC-seq and nucleosome plasma mapping, i.e., GRHL2, EVX2, DLX2, HNF4A, LYL1, and PU.1 (Fig. 3c, e).